Trial Profile

Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 09 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rhenium 188 P 2045 (Primary)
Indications Adenocarcinoma; Large cell carcinoma; Non-small cell lung cancer; Small cell lung cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Andarix Pharmaceuticals; Bayer; Bayer HealthCare Pharmaceuticals Inc.

Most Recent Events

31 Oct 2022 Status changed to recruiting.
31 Oct 2022 Planned End Date changed from 1 Apr 2020 to 20 Apr 2025.
29 May 2009 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com